Free press releases distribution network?

Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Novozymes Biopharma Announces New Study Data Using Recombumin in Protein Drug Formulation - Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, announces new data which demonstrates extended shelf life of protein drug products using Recombumin, recombinant human albumin
Novozymes Biopharma Announces New Study Data Using Recombumin in Protein Drug Formulation

 

PRZOOM - /newswire/ - Nottingham, United Kingdom, 2010/03/24 - Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, announces new data which demonstrates extended shelf life of protein drug products using Recombumin, recombinant human albumin.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The data, presented for the first time at a recent protein-focused industry event, reveals the potential for Recombumin to reduce product loss by preventing the physical and chemical degradation of protein drugs.

A data sheet entitled "Recombumin®: A pharmaceutical excipient in the stabilization of therapeutic protein products" details the findings. The study investigated the ability of Recombumin, a recombinant human albumin expressed in Saccharomyces cerevisiae, to prevent the deterioration of protein drug products in a variety of test formulations. The study particularly addressed Recombumin's minimization of surface adsorption, oxidation and aggregation in comparison to excipients commonly used for the purpose of formulating protein drugs.

The new data demonstrates that Recombumin has the capacity to improve the shelf life of protein drug products. The study's findings indicate that Recombumin performed as well as and often better than the comparators making it an effective multi-purpose excipient with the capability to reduce the total number of excipients required and therefore simplifying the formulation strategy.

Derived from Novozymes Biopharma's proprietary yeast expression technology, Recombumin is the world's leading animal-free, commercially available recombinant human albumin used in the manufacture of licensed and developmental human therapeutics. Offering the stabilizing benefits of albumin in a GMP compliant and regulatory package, Recombumin ensures high performance and security of long term supply. Its compliance with the excipient monograph for recombinant human albumin published in the United States Pharmacopoeia - National Formulary (USP-NF) also eases the regulatory process for customers and sets the industry benchmark for recombinant human albumin.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma Announces New Study Data Using Recombumin in Protein Drug Formulation

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Fiona Robinson 
+44 115 955 3355 SYKE[.]novozymes.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Al Rowaad Advocates & Legal Consultants







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today